Merck Invests $1 Billion in New U.S. Manufacturing Facility Amid Trade Policy Shifts

Merck plans to expand its manufacturing capabilities in the United States with a new $1 billion facility. This investment positions Merck as the most recent pharmaceutical company to increase its domestic manufacturing presence amid evolving trade policies. The company’s decision to build the new plant reflects a broader trend within the pharmaceutical industry to bolster U.S.-based production. The expansion occurs as tariffs on imported goods are under consideration, potentially impacting the supply chain and costs associated with manufacturing drugs overseas. Merck’s significant financial commitment to the new facility signals a strategic move to strengthen its American manufacturing base.

Newsflash | Powered by GeneOnline AI
Date: April 29, 2025

Related posts:

AACR Meeting Spotlights New Cancer Drug, Early Detection Tool, Canine Scent Research, and Vaccine Data AI Models Improve Cancer Cachexia Detection by Analyzing Biomarkers for Muscle Atrophy Eli Lilly to lead oligonucleotide therapy development in new collaboration Cimerli Biosimilar Targets Vision Loss in Age-Related Macular Degeneration Through VEGF Inhibition

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後